

Multiple reports of symptom exacerbation on immunostimulatory treatment for autoimmune disease



Paul Albert, Weill Cornell Medical College

Over the past seven years, we have been observing patients with autoimmune diagnoses use the VDR-agonist olmesartan to stimulate components of the innate immune response. Nearly all of the hundreds of patient reported outcomes describe an initial increase in symptoms specific to their autoimmune diagnoses. Additionally, patients consistently report fluctuations in objective markers of inflammation such as CRP, ACE, BUN, creatinine, and markers of liver function. After months of dealing with these fluctuations in disease state, symptomatic improvements begin to be reported, in some cases with objective markers indicating disease stabilization or remission. These symptomatic flares cannot easily be attributed to adverse events from olmesartan, as the drug is well known and unremarkable. Additionally, when healthy individuals have been

administered the same medications, they suffer no similar symptoms. The most viable hypothesis for these symptomatic flares is that, by activating the innate immune system, olmesartan allows the body to mount an effective attack against pathogenic components of the microbiota. For a century, researchers have noted that death of acute and persistent pathogens is accompanied by a surge in inflammation, endotoxin, and cytokine release. Known as Jarisch-Herxheimer, or immunopathology, this phenomenon has been demonstrated in numerous diseases. Olmesartan seems to be generating immunopathology. These preliminary results also indicate immunopathology may be a necessary part of reducing the metagenomic load in patients with autoimmune diagnoses.

Changes in Antibodies

Female, 49, Hashimoto's Thyroiditis

Date	ANA titer
Sept. 2004	200 IU/ml Begins Protocol
July 2005	217 IU/ml
Oct. 2005	51 IU/ml

Female, 55, Hashimoto's Thyroiditis

Date	Peroxidase
Nov. 2004	>1,000 Diagnosis
Feb. 2006	2,000 Begins Protocol
Jan. 2009	232

Female, 58, Rheumatoid Arthritis

Date	Thyroglobulin
Aug. 2004	1:160 Begins Protocol
Mar. 2005	1:320
Aug. 2005	1:160
Nov. 2006	negative
<i>8 subsequent tests also negative</i>	

Changes in Other Markers of Inflammation

Male, 56, Sarcoidosis

Upon starting the treatment in December 2005, this patient's renal function began to decline and reach the upper limit of normal - BUN 20mg/dL, GFR >60ml/min/1.73m², CR 1.3mg/dL. As he managed immunopathology over the next two years, his kidney function continued to steadily decline. In October 2007, his kidney function had reached its lowest point - BUN 29mg/dL, GFR 42ml/min/1.73m², CR 1.8mg/dL. Yet the patient continued the Protocol, and since October 2007 has shown a steady improvement in renal function. In August 2008, BUN was 17mg/dL, GFR 52ml/min/1.73m², and CR 1.5mg/dL. He is now 95% free of his previous symptoms and no longer takes oral or inhaled steroids. We hypothesize his rise in BUN, etc. corresponded to a period of high bacterial death and increased inflammation that subsequently subsided as pathogens were killed. Indeed, doctors who have allowed patients to continue the Protocol despite fluctuations in blood work generally find that patients remain unharmed and that markers eventually fall back into a permanently healthy range.

Female, 46, CFS and Fibromyalgia

This patient experienced steady immunopathology from treatment start. During her third year of the treatment, she experienced a rise in liver enzymes lasting approximately four months: ALT reached a peak of 202 IU/L, while AST reached 270 IU/L. However these measures normalized in the following months. Currently, at 38 months on the Protocol, her chronic headaches have disappeared and she no longer suffers from asthma, frequent viral gastrointestinal illnesses and recurrent bouts of pneumonia and bronchitis. Her cognitive abilities, pain and fatigue have improved dramatically.

Safety Profile of Olmesartan

- In placebo-controlled trials, the only side effect that occurred in >1% of olmesartan-treated patients vs. placebo-treated patients was dizziness (3% vs. 1%).
- Frequency of adverse events is not dose related.
- Olmesartan, with or without hydrochlorothiazide, was well tolerated over two years of treatment.

Source: Clin Ther. 2004;26 Suppl A:A28-32.

- Olmesartan has no clinically significant effects on laboratory parameters.

Source: J Hum Hypertens. 2002;16 Suppl 2:S13-6.

- CS-866 [olmesartan] was safe and well tolerated at doses of up to 160 mg/day.... [Olmesartan] has no serious adverse effects.

Source: J Clin Pharmacol. 2001;41:515-27.

Future Directions

This profound reaction occurs in ~98% of patients with chronic disease. Help us characterize how this treatment affects microbial populations.